Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Garden City, NY
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Garden City, NY
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Great Neck, NY
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Great Neck, NY
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
New York, NY
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Poughkeepsie, NY
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Staten Island, NY
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Staten Island, NY
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Syracuse, NY
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Cary, NC
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Cary, NC
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Greenville, NC
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Greenville, NC
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Raleigh, NC
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Winston-Salem, NC
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Cincinnati, OH
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Columbus, OH
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Sheffield Village, OH
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Sheffield Village, OH
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Poca City, OK
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Poca City, OK
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Portland, OR
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Bala Cynwyd, PA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Lancaster, PA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Lancaster, PA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Philadelphia, PA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
State College, PA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
State College, PA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Providence, RI
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Myrtle Beach, SC
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Simpsonville, SC
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Simpsonville, SC
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Nashville, TN
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Norfolk, VA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Richmond, VA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Virginia Beach, VA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Seattle, WA
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Milwaukee, WI
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated:  11/30/2016
GSK Investigational Site
mi
from
Av Córdoba 2424,
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
Status: Enrolling
Updated: 11/30/2016
GSK Investigational Site
mi
from
Av Córdoba 2424,
Click here to add this to my saved trials
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies
Status: Enrolling
Updated:  12/1/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies
Status: Enrolling
Updated: 12/1/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pillars4Life Trial
Pillars4Life Randomized Control Trial
Status: Enrolling
Updated:  12/6/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Pillars4Life Trial
Pillars4Life Randomized Control Trial
Status: Enrolling
Updated: 12/6/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
MRI Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
MRI (Magnetic Resonance Imaging) Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
Status: Enrolling
Updated:  12/12/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
MRI Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
MRI (Magnetic Resonance Imaging) Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
Status: Enrolling
Updated: 12/12/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Addressing Prostate Cancer Information Disparities With eHealth Technology
Addressing Prostate Cancer Information Disparities With eHealth Technology
Status: Enrolling
Updated:  12/21/2016
Tufts University
mi
from
Medford, MA
Addressing Prostate Cancer Information Disparities With eHealth Technology
Addressing Prostate Cancer Information Disparities With eHealth Technology
Status: Enrolling
Updated: 12/21/2016
Tufts University
mi
from
Medford, MA
Click here to add this to my saved trials
Addressing Prostate Cancer Information Disparities With eHealth Technology
Addressing Prostate Cancer Information Disparities With eHealth Technology
Status: Enrolling
Updated:  12/21/2016
Emory University Hospital
mi
from
Atlanta, VA
Addressing Prostate Cancer Information Disparities With eHealth Technology
Addressing Prostate Cancer Information Disparities With eHealth Technology
Status: Enrolling
Updated: 12/21/2016
Emory University Hospital
mi
from
Atlanta, VA
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
University of Chicago
mi
from
Chicago, IL
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Johns Hopkins University
mi
from
Baltimore, MD
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
University of Michigan
mi
from
Ann Arbor, MI
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Washington University
mi
from
St. Louis, MO
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
University of Rochester
mi
from
Rochester, NY
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Ohio State University
mi
from
Columbus, OH
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
University of Alabama
mi
from
Birmingham, AL
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated:  12/22/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Status: Enrolling
Updated: 12/22/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated:  1/3/2017
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated: 1/3/2017
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials